Abstract:
The invention described herein includes a molecular switch, comprising: a donor subunit; an acceptor subunit; and an aromatic bridging subunit comprising one or more bridging groups for bonding the donor subunit to the aromatic bridging subunit and for bonding the acceptor subunit to the aromatic bridging subunit wherein the aromatic bridging subunit is conformable in a manner effective for polarizing and de-polarizing the molecular switch at a low electric field voltage.
Abstract:
The present invention is drawn to compositions and methods of generating active ester functionalized latex particulates in a liquid suspension, as well as compositions and methods of preparing ink-jet inks. Steps of the methods can include synthesizing polymerizable monomers with active ester groups and polymerizing these monomers with other monomers to form functionalized latex particulates having active ester group. These latex particulates can be used in a wide variety of applications, including in ink-jet ink printing applications.
Abstract:
A digital dye having an optical change resulting from an electrochemical oxidation/reduction reaction is provided for use in a molecular system. The molecular system provides two different colors based on two different oxidation states of at least one digital dye in the molecular system. Further, an optical switch comprising the molecular system configured within an electric field generated by a pair of electrodes is provided, employing the above-described digital dye. Still further, a display device including a transparent display electrode, a counter electrode, and the molecular system disposed therebetween is provided, where the molecular system comprises at least one digital dye.
Abstract:
A self-assembled molecular color switch is formed on a substrate and comprises coupled coaxial rotors and non-coaxial stators, with each rotor rotatably connected to two stators, to form molecular planes wherein all rotors at rest are parallel to the substrate and orthogonal to an electric field. The color switch employs a novel chemistry for producing a molecular film having a field switchable color. More particularly, it is a chemistry that provides for relatively thick self-assembled molecular layers collectively having print-like optical density. Further, a means for bi-stable color switching is provided.
Abstract:
Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using the 4-substituted piperidine analogs as selectively active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as cerebral ischemia, central nervous system trauma, hypoglycemia, neurodegenerative disorders, anxiety, migraine headaches, convulsions, aminoglycoside antibiotics-induced hearing loss, chronic pain, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, urinary incontinence and neurodegenerative disorders such as lathyrism, Alzheimers' Disease, Parkinsonism, and Huntington's Disease are described. Also described are novel methods for preparing 4-substituted piperidine analogs and novel intermediates of the 4-substituted piperidine analogs.
Abstract:
Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 4-substituted piperidine analogs as selectively active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, anxiety, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headaches, glaucoma, CMV retinitis, chronic pain, opioid tolerance or withdrawals, or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described. Also described are novel methods for preparing 4-substituted piperidine analogs and novel intermediates of the 4-substituted piperidine analogs.
Abstract:
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia, and treating or preventing opiate tolerance are disclosed by administering to an animal in need of such treatment or prevention a substituted or unsubstituted pyridine and pyridine (N-oxide) analogs of 4-hydroxydihydroquinolones, tetrahydroquinoline-trione-oximes and quinoxalones, tautomers and pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.
Abstract:
The present disclosure is related to coated photoconductors. In an example, a coated photoconductor can comprise a photoconductor including a substrate having a charge generation layer and charge transport layer adhered thereto and a top coating adhered to the photoconductor. The top coating can comprise a cross-linkable polymer, a cross-linker, and a polymeric dopant having a weight average molecular weight of less than 500,000. Additionally, the top coating can have a thickness of 0.1 μm to 12 μm and the polymeric dopant can be present in the top coating at a concentration of 0.1 wt % to 10 wt %.
Abstract:
Surfactants are provided that have a hydrophobic tail portion and a hydrophilic head portion. The hydrophilic head portion includes a terminal dialkyl-substituted tertiary amine or a terminal cycloalkyl-substituted tertiary amine. Also provided are pigment-based inks employing the surfactant, a combination of an electronic display and the pigment-based inks, and a process for reducing conductivity in primary amine-based surfactants and improving reliability of electronic inks employing such surfactants.
Abstract:
Pigment based inks are provided. The inks include a non-polar carrier fluid and a surface-functionalized pigment particle including a nitrogen-linked moiety to the surface of the pigment particle through a nitrogen link at one end of the nitrogen-linked moiety and a graft copolymer having two or three blocks attached at another end, the pigment particle suspended in the non-polar carrier fluid, the nitrogen-linked moiety further including an alkyl chain interposed between the nitrogen-linked moiety and the graft copolymer having the structure (I), where X is the nitrogen-linked moiety and Y is a copolymer, and the letter a is an integer between 0 and about 5,000, while the letter b is an integer of 2 or more.